• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Akari Therapeutics plc (Amendment)

    4/14/23 4:06:36 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AKTX alert in real time by email
    SC 13D/A 1 tm2312911d1_sc13da.htm SC 13D/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 5)*

     

    Akari Therapeutics, Plc

    (Name of Issuer)

     

    Ordinary Shares, $0.0001 par value

    (Title of Class of Securities)

     

    00972G108

    (CUSIP Number)

     

    Gary Emmanuel, Esquire

    Greenberg Traurig, LLP

    One Vanderbilt Avenue

    New York, NY 10017

    +1 212 801 9337

     

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

     

    March 31, 2023

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 00972G108 SC 13D/A Page 2 of 7 Pages

     

    1.

    Names of Reporting Persons.

     

    Ray Prudo, M.D.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ¨

    (b) x

    3.

    SEC Use Only

     

     

    4.

    Source of Funds (See Instructions)

     

    OO

    5.

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

    ¨

    6.

    Citizenship or Place of Organization

     

    Canada

    Number
    of Shares
    Beneficially
    Owned
    by Each
    Reporting
    Person With:
    7.

    Sole Voting Power

     

    1,455,428,700

    8.

    Shared Voting Power

     

    2,294,904,900

    9.

    Sole Dispositive Power

     

    1,455,428,700

    10.

    Shared Dispositive Power

     

    2,294,904,900

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,294,904,900

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

    ¨

    13.

    Percent of Class Represented by Amount in Row (11)

     

    22.7%

    14.

    Type of Reporting Person (See Instructions)

     

    IN

     

     

     

     

    CUSIP No. 00972G108 SC 13D/A Page 3 of 7 Pages

     

    1.

    Names of Reporting Persons.

     

    RPC Pharma Limited

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ¨

    (b) x

    3.

    SEC Use Only

     

     

    4.

    Source of Funds (See Instructions)

     

    OO

    5.

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

    ¨

    6.

    Citizenship or Place of Organization

     

    Malta

    Number
    of Shares
    Beneficially
    Owned
    by Each
    Reporting
    Person With:
    7.

    Sole Voting Power

     

    0

    8.

    Shared Voting Power

     

    800,766,600

    9.

    Sole Dispositive Power

     

    0

    10.

    Shared Dispositive Power

     

    800,766,600

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    800,766,600

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

    ¨

    13.

    Percent of Class Represented by Amount in Row (11)

     

    7.9%

    14.

    Type of Reporting Person (See Instructions)

     

    CO

     

     

     

     

    CUSIP No. 00972G108 SC 13D/A Page 4 of 7 Pages

     

    1.

    Names of Reporting Persons.

     

    Praxis Trustees Limited As trustee of The Sonic Healthcare Holding Company

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ¨

    (b) x

    3.

    SEC Use Only

     

     

    4.

    Source of Funds (See Instructions)

     

    OO

    5.

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

    ¨

    6.

    Citizenship or Place of Organization

     

    Guernsey

    Number
    of Shares
    Beneficially
    Owned
    by Each
    Reporting
    Person With:
    7.

    Sole Voting Power

     

    0

    8.

    Shared Voting Power

     

    38,709,600

    9.

    Sole Dispositive Power

     

    0

    10.

    Shared Dispositive Power

     

    38,709,600

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    38,709,600

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

    ¨

    13.

    Percent of Class Represented by Amount in Row (11)

     

    0.4%

    14.

    Type of Reporting Person (See Instructions)

     

    OO

     

     

     

     

    CUSIP No. 00972G108 SC 13D/A Page 5 of 7 Pages

     

    Introduction

     

    This Amendment No. 5 to Schedule 13D (this “Amendment No. 5”) amends and supplements where indicated the Statement on Schedule 13D originally filed with the Securities and Exchange Commission on September 29, 2015 and amended on October 26, 2017, March 30, 2020, October 18, 2021, and January 14, 2022, respectively (collectively, the “Prior Schedule 13D”) by and on behalf of RPC Pharma Limited, a Maltese corporation (“RPC”), Ray Prudo, M.D., a citizen of Canada (“Dr. Prudo”) and Praxis Trustees Limited As trustee of The Sonic Healthcare Holding Company (“Praxis,” and together with RPC, and Dr. Prudo, the “Prior Reporting Persons”), and relates to the ordinary shares, par value $0.0001 (“Ordinary Shares”) of Akari Therapeutics, Plc, a public limited company formed under the laws of England and Wales (the “Issuer”). The Issuer's American Depositary Shares, each representing 100 Ordinary Shares (the "ADSs"), have been registered on a registration statement on Form F-6 (File No. 333-185197), as supplemented (File Nos. 333-234213 and 333-262049), and trade on the Nasdaq Capital Market under the symbol "AKTX."

     

    Capitalized terms used herein but not defined herein shall have the meanings ascribed to them in the Prior Schedule 13D. This Amendment No. 5 amends and supplements the Prior Schedule 13D as specifically set forth herein. Except as set forth below, all previous Items in the Prior Schedule 13D remain unchanged.

     

    This Amendment No. 5 is being filed to amend Items 3, 4 and 5 as set forth below and to update the number of shares of Ordinary Shares beneficially held by the Reporting Persons as a result of the transaction described below.

     

    Item 3. Source and Amount of Funds or Other Consideration.

     

    Item 3 of the Prior Schedule 13D is hereby supplemented by adding the following paragraph:

     

    On March 8, 2022, pursuant to a registered direct offering (the “March 2022 Registered Direct Offering”) of 7,440,833 of the Issuer’s ADSs, Dr. Prudo purchased 833,334 ADSs at a price of $1.20 per ADS. The funds used by Dr. Prudo to acquire the ADSs were from his personal funds. In connection with the sale of the ADSs in the March 2022 Registered Direct Offering, Dr. Prudo was also issued registered warrants to purchase an aggregate of 416,667 ADSs at a price of $1.65 per ADS in the March 2022 Registered Direct Offering. The warrants were immediately exercisable.

     

    On September 12, 2022, pursuant to a registered direct offering (the “September 2022 Registered Direct Offering”) of 15,100,000 of the Issuer’s ADSs, Dr. Prudo purchased 1,176,471 ADSs at a price of $0.85 per ADS. The funds used by Dr. Prudo to acquire the ADSs were from his personal funds. In a concurrent private placement (the “September 2022 Private Offering”), Dr. Prudo was also issued unregistered warrants to purchase an aggregate of 2,352,942 ADSs at a price of $0.85 per ADS, and such ADSs were registered for resale pursuant to a registration statement on Form F-1 (File No. 333-267840). The warrants were immediately exercisable.

     

    On March 30, 2023, pursuant to a registered direct offering (the “March 2023 Registered Direct Offering”) of 26,666,667 of the Issuer’s ADSs, Dr. Prudo purchased 8,666,666 ADSs at a price of $0.15 per ADS.

     

    The funds used by Dr. Prudo to acquire the ADSs and warrants described in Item 3 of this Amendment No. 5 were from his personal funds.

     

    Item 4. Purpose of Transaction.

     

    Item 4 of the Prior Schedule 13D is hereby supplemented by adding the following paragraph:

     

    On March 8, 2022, Dr. Prudo purchased 833,334 ADSs and was issued warrants to purchase 416,667 ADSs in the March 2022 Registered Direct Offering described above. On September 12, 2022, Dr. Prudo purchased 1,176,471 ADSs and warrants to purchase 2,352,942 ADSs in the September 2022 Registered Direct Offering and September 2022 Private Offering described above, respectively. On March 30, 2023, Dr. Prudo purchased 8,666,666 ADSs in the March 2023 Registered Direct Offering described above.

     

     

     

     

    CUSIP No. 00972G108 SC 13D/A Page 6 of 7 Pages

     

    Item 5. Interest in Securities of the Issuer.

     

    (a) In his individual capacity, Dr. Prudo beneficially owns the 2,294,904,900 Ordinary Shares reported on the first cover page, which represents approximately 22.7% of the Issuer’s Ordinary Shares. RPC beneficially owns the 800,766,600 Ordinary Shares reported on the second cover page, which represents approximately 7.9% of the Issuer’s Ordinary Shares. Voting and investment decisions with respect to such shares are controlled by Dr. Prudo. Praxis beneficially owns the 38,709,600 Ordinary Shares reported on the third cover page, which represents approximately 0.4% of the Issuer’s Ordinary Shares. Voting and investment decisions with respect to such shares are controlled by Dr. Prudo. The percentage of beneficial ownership reported on the Reporting Persons’ cover pages to this Amendment No. 5 is based on 10,111,583,823 Ordinary Shares outstanding as of March 31, 2023 (as reported in the Issuer’s Prospectus Supplement Form 424B5 filed on March 31, 2023).

     

    (b)

     

    Reporting Person Sole Voting Power Shared Voting Power

    Sole Dispositive

    Power

    Shared Dispositive Power
    Ray Prudo, M.D. 1,455,428,700 2,294,904,900 1,455,428,700 2,294,904,900
    RPC Pharma Limited 0 800,766,600 0 800,766,600
    Praxis 0 38,709,600 0 38,709,600

     

    (c) On March 8, 2022, Dr. Prudo purchased 833,334 ADSs and was issued warrants to purchase 416,667 ADSs in the March 2022 Registered Direct Offering described above. On September 12, 2022, Dr. Prudo purchased 1,176,471 ADSs and warrants to purchase 2,352,942 ADSs in the September 2022 Registered Direct Offering and September 2022 Private Offering described above, respectively. On March 30, 2023, Dr. Prudo purchased 8,666,666 ADSs in the March 2023 Registered Direct Offering described above. None of the Reporting Persons has effected any other transactions in shares of the Common Stock during the 60 days prior to the filing of this Amendment No. 5.

     

    (d) No person other than the Reporting Persons is known to have the right to receive or the power to direct the receipt of dividends or the proceeds from the sale of any Ordinary Shares.

     

    (e) Not applicable.

     

     

     

     

    CUSIP No. 00972G108 SC 13D/A Page 7 of 7 Pages

     

    Signatures

     

    After reasonable inquiry and to the best of the undersigned’s knowledge and belief, each of the undersigned hereby certifies that the information set forth in this statement is true, complete and correct.

     

         
    Dated April 14, 2023 By: /s/ Ray Prudo
      RAY PRUDO, M.D.
       
    Dated: April 14, 2023 RPC PHARMA LIMITED
         
      By: /s/ Ray Prudo
      Name: Ray Prudo, M.D.
      Title: Authorized Person  
       
    Dated: April 14, 2023 Praxis Trustees Limited As trustee of The Sonic Healthcare Holding Company
         
      By: /s/ Blaine Queripel
      Name: Blane Queripel
      Title: Trustee Director

     

     

     

    Get the next $AKTX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKTX

    DatePrice TargetRatingAnalyst
    7/18/2025$5.00Buy
    Maxim Group
    More analyst ratings

    $AKTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Akari Therapeutics to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

    BOSTON and LONDON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biotechnology company developing novel Antibody Drug Conjugates (ADCs) with immuno-oncology payloads for the treatment of cancer, today announced that it will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech being held virtually August 19-21, 2025. Details for the presentation are as follows: Date and Time: Tuesday, August 19, 2025 at 2:00 PM ET Presenter: Abizer Gaslightwala, President and Chief Executive Officer of AkariRegistration Link: HERE About Webull Financial Webull Financial is a leading online brokerage platform committed to empowering self-directed

    8/14/25 9:15:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akari Therapeutics Releases Virtual Investor "What This Means" Segment

    Watch the "What This Means" video here BOSTON and LONDON, July 29, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel immuno-oncology payload antibody drug conjugates (ADCs) for the treatment of cancer, today announced that Abizer Gaslightwala, President and CEO of Akari Therapeutics participated in a Virtual Investor "What This Means" segment. As part of the segment, Mr. Gaslightwala discussed its novel spliceosome modulator payload, PH1, and the Company's ongoing efforts to build on key data for its spliceosome modulator payload with further research ongoing on how the payload can also disrupt key drivers responsible for c

    7/29/25 9:15:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers

    PH1 modulates RNA splicing, causing cancer cell death while activating the immune system to attack cancer throughout the body Company advancing pipeline of ADCs using PH1 payload across both Trop2 and an undisclosed target Emerging new preclinical data on impact of PH1 payload against a key oncogenic driver is expected before year-end BOSTON and LONDON, July 23, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel immuno-oncology payload antibody drug conjugates (ADCs) for the treatment of cancer, today reiterated its commitment to ongoing research to better understand the multiple effects of its novel spliceosome modulator,

    7/23/25 8:55:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Gaslightwala Abizer bought $7,120 worth of American Depositary Shares representing Ordinary Shares (6,146 units at $1.16), increasing direct ownership by 2% to 277,574 units (SEC Form 4)

    4 - Akari Therapeutics Plc (0001541157) (Issuer)

    6/25/25 4:30:04 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Gaslightwala Abizer bought $12,000 worth of American Depositary Shares representing Ordinary Shares (10,000 units at $1.20), increasing direct ownership by 4% to 271,428 units (SEC Form 4)

    4 - Akari Therapeutics Plc (0001541157) (Issuer)

    6/24/25 4:30:10 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Gaslightwala Abizer bought $18,000 worth of American Depositary Shares representing Ordinary Shares (15,000 units at $1.20), increasing direct ownership by 6% to 261,428 units (SEC Form 4)

    4 - Akari Therapeutics Plc (0001541157) (Issuer)

    6/20/25 4:05:04 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on Akari Therapeutics with a new price target

    Maxim Group initiated coverage of Akari Therapeutics with a rating of Buy and set a new price target of $5.00

    7/18/25 9:02:34 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTX
    SEC Filings

    View All

    Akari Therapeutics plc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Akari Therapeutics Plc (0001541157) (Filer)

    8/19/25 8:00:23 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Akari Therapeutics plc

    10-Q - Akari Therapeutics Plc (0001541157) (Filer)

    8/13/25 5:01:23 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Akari Therapeutics plc

    EFFECT - Akari Therapeutics Plc (0001541157) (Filer)

    8/1/25 12:15:28 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Gaslightwala Abizer bought $7,120 worth of American Depositary Shares representing Ordinary Shares (6,146 units at $1.16), increasing direct ownership by 2% to 277,574 units (SEC Form 4)

    4 - Akari Therapeutics Plc (0001541157) (Issuer)

    6/25/25 4:30:04 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Gaslightwala Abizer bought $12,000 worth of American Depositary Shares representing Ordinary Shares (10,000 units at $1.20), increasing direct ownership by 4% to 271,428 units (SEC Form 4)

    4 - Akari Therapeutics Plc (0001541157) (Issuer)

    6/24/25 4:30:10 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Gaslightwala Abizer bought $18,000 worth of American Depositary Shares representing Ordinary Shares (15,000 units at $1.20), increasing direct ownership by 6% to 261,428 units (SEC Form 4)

    4 - Akari Therapeutics Plc (0001541157) (Issuer)

    6/20/25 4:05:04 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTX
    Financials

    Live finance-specific insights

    View All

    Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger

    BOSTON and LONDON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announces shareholder approval in connection with the merger of Akari Therapeutics, Plc (the Company) and Peak Bio, Inc. At a General Meeting held in relation to the merger at 9:00 a.m. Eastern Time on Thursday, November 7, 2024 at the Company's offices in London, shareholders approved the Company's issuance of shares in connection with the proposed merger, with approximately 99% of shares present at the General Meeting, in person or by proxy, voted in support. "I am thrilled to announce this

    11/8/24 8:00:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio Merger

    BOSTON and LONDON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announces the effectiveness of the Form S-4, originally filed with the SEC on September 13, 2024 related to the merger of Akari Therapeutics, Plc (the Company) and Peak Bio, Inc. The Form S-4 was declared effective by the SEC on October 11, 2024 allowing the Company to definitively schedule the General Meeting to be held in relation to the merger. The General Meeting will be held at 9:00 a.m. Eastern Time on Thursday, November 7, 2024 at the Company's offices in London. "I am so excited to be

    10/15/24 8:00:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akari Therapeutics Announces Interim CEO Employment Contract Demonstrating Alignment with Shareholders

    Interim CEO employment contract consists solely of equity compensationSamir R. Patel, M.D., increases ownership to 14.2% with $1.25m investment in recent private placement BOSTON and LONDON, June 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (NASDAQ:AKTX), an innovative biotechnology company advancing therapies for autoimmune and inflammatory diseases, in follow up to the May 1st announcement that Samir R. Patel, M.D., has assumed the role of Interim President & CEO, provides detail of Dr. Patel's employment compensation. Dr Patel's employment contract reaffirms his desire to align his success directly with the success of the company's shareholders. Dr. Patel will be compen

    6/5/24 8:00:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Akari Therapeutics plc

    SC 13D/A - Akari Therapeutics Plc (0001541157) (Subject)

    12/6/24 4:00:28 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Akari Therapeutics plc

    SC 13D/A - Akari Therapeutics Plc (0001541157) (Subject)

    6/20/24 7:30:07 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Akari Therapeutics plc

    SC 13D - Akari Therapeutics Plc (0001541157) (Subject)

    6/18/24 4:15:30 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTX
    Leadership Updates

    Live Leadership Updates

    View All

    Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

    NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rachelle Jacques as Chair of its Board of Directors, effective May 15. She succeeds Alan Holmer, who will remain on the Board. "We thank Alan for his over ten years of dedicated service as founding Chair of the Corbus Board," said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. "Rachelle is a seasoned biopharmaceutical executive, and we have greatly benefitted from her innovative and strategic thinking as a Board member.  We look forward to following her vision and continued leadership as we

    5/19/25 8:00:00 AM ET
    $AKTX
    $CRBP
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development - Oncology

    Global expertise in establishing and executing transformative transactions which have led to multiple approved therapeutic products Successful track record across oncology therapeutics including ADCs and antibody therapies ranging from early discovery to pre-clinical/clinical stage 25+ year-career experience bolsters Company's efforts to address growing, high-value ADC market and maximize opportunities for non-dilutive capital BOSTON and LONDON, May 01, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced the appointment of Mark F. Kubik as Head of Business Development

    5/1/25 8:45:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akari Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

    Advancing development of next-generation precision Antibody Drug Conjugates (ADCs) to address multiple indications across a range of cancer types Continued progress of lead program, AKTX-101, for the treatment of solid tumors Platform technology to fuel pipeline with ability to generate novel ADC candidates across a range of solid/hematological cancers Leveraging opportunities for non-dilutive capital through partnering of legacy pipeline Cash on hand expected to be sufficient to fund planned operations into September 2025 BOSTON and LONDON, April 16, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biotechnology company developing next-generation precision bi-fun

    4/16/25 8:00:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care